ACINETOBACTER BAUMANNII [67-1], [117-1], [162-1]
ACINETOBACTER SPP. [130-1]
AEROMONAS VERONII [201-1]
AGGREGATIBACTER ACTINOMYCETEMCOMITANS [204-1]
AIRBORNE INFECTION [146-1]
ANDRADE SCREENING ANTIMICROBIAL TEST [98-1]
ANTAGONISTIC ACTIVITY [202-1]
ANTI-INFECTIVE AGENTS [206-1]
ANTIBIOFILM [198-1]
ANTIBIOTIC COMBINATION [40-1]
ANTIBIOTIC RESISTANCE [75-1], [123-1]
ANTIBIOTIC SUSCEPTIBILITY [134-1]
ANTIBIOTICS [96-1]
ANTIFUNGAL [137-1], [198-1]
ANTIFUNGAL ACTIVITY [39-1], [90-1]
ANTIFUNGALS [199-1]
ANTIMICROBIAL ACTIVITY [108-1], [202-1], [220-1]
ANTIMICROBIAL RESISTANCE [11-1], [105-1], [114-1], [115-1], [117-1], [130-1], [140-1], [143-1], [149-1], [159-1], [165-1], [195-1]
ANTIMICROBIAL RESISTANCE PROFILES [36-1]
ANTIMICROBIAL RESISTANCE4 [222-1]
ANTIMICROBIAL SUSCEPTIBILITY [65-1], [67-1], [154-1]
ANTIMICROBIAL SUSCEPTIBILITY TEST [22-1]
ANTIMICROBIAL SUSCEPTIBILITY TESTING [103-1]
ANTIOXIDANTS [206-1]
AQUEOUS HUMOR [106-1]
ARMA [162-1]
ARTABOTRYS BRACHYPETALUS BENTH. [37-1]
ASPERGILLUS [229-1]
ATOPIC DERMATITIS [154-1]
BACTERIA [128-1]
BACTERIAL COINFECTION [114-1]
BACTERIAL COINFECTIONS [165-1]
BACTERIAL RESISTANCE [102-1], [139-1], [178-1]
BACTERIAL RESISTANCE TO ANTIBIOTICS [68-1]
BARBATIMAO [137-1]
BATS [128-1]
BENZOFUROXAN [113-1]
BETA-LACTAMASES [217-1]
BIOCIDES [79-1]
BIOFILM [44-1], [147-1], [178-1], [222-1], [223-1]
BIOFILMS [80-1]
BIOGENIC SILVER NANOPARTICLES [198-1]
BLAKPC [49-1]
BLANDM [49-1]
BLANDM GENE [153-1]
BLOOD CULTURE [103-1], [121-1]
BLOOD SURVIVAL [221-1]
BLOODSTREAM INFECTION [133-1]
BROMELAIN AND ACETYLCYSTEINE [220-1]
BROTH MICRODILUTION [111-1], [225-1]
BURKHOLDERIA AMBIFARIA [35-1]
BURKHOLDERIA CEPACIA COMPLEX [35-1]
BURKHOLDERIA SP [120-1]
CANCER [80-1]
CANDIDA [90-1], [142-1]
CANDIDA ALBICANS [80-1], [127-1], [137-1], [204-1]
CANDIDA AURIS [198-1], [199-1]
CANDIDA PARAPSILOSIS COMPLEX [223-1]
CANDIDA SPP [44-1]
CANDIDA SPP. [37-1]
CANDIDEMIA [226-1]
CAPSULAR SOROTYPE [160-1]
CARBAPENEM [117-1]
CARBAPENEM RESISTANCE [169-1]
CARBAPENEM-RESISTANCE [130-1]
CARBAPENEM-RESISTANT [159-1], [161-1]
CARBAPENEMASE [83-1], [96-1], [134-1]
CARBAPENEMASES [49-1]
CARBAPENEMS [96-1]
CARDIOVASCULAR INFECTIONS [200-1]
CEARA [128-1]
CEFTAZIDIME-AVIBACTAM [134-1]
CEFTAZIDIME/AVIBACTAM [103-1]
CEFTAZIDIME/AVIBACTAM RESISTANCE [169-1]
CEFTOLOZANE-TAZOBACTAM [104-1]
CHOCOLATE AGAR [22-1]
CLASS 1 INTEGRON [201-1]
CLINICAL METAGENOMICS [219-1], [231-1]
CLINICAL MICROBIOME [219-1], [231-1]
CLONAL LINEAGES [154-1]
CLONAL RELATEDNESS [67-1]
CLOTRIMAZOLE [44-1]
CLUSTERS [151-1]
COAGULASE NEGATIVE STAPHYLOCOCCUS [143-1]
COAGULASE-NEGATIVE STAPHYLOCOCCI [51-1]
COALHO CHEESE [65-1]
COLISTIN [117-1]
COLISTIN; POLI-NP [98-1]
COLORIMETRIC METHOD [176-1]
COMPLEMENT [200-1]
COVID-19 [67-1], [114-1], [129-1], [133-1], [162-1], [165-1], [185-1]
COVID-19, [70-1]
CRISPR-CAS9 [123-1]
CROSS-CONTAMINATION [186-1]
CULTURE-INDEPENDENT TECHNIQUE [120-1]
CYST [74-1]
CYSTIC FIBROSIS [120-1]
DERMATOPHYTOSIS [39-1]
DIABETES [131-1]
DIAGNOSTICS [129-1]
DIPICOLINIC ACID [176-1]
DISINFECTION [222-1]
DISK DIFFUSION [224-1]
DISK-ELUTION METHOD [98-1]
DR4 [59-1]
DR5 [59-1]
DRUG DISCOVERY [113-1]
DRUG REPOSITIONING [147-1]
DRUG RESISTANCE [66-1]
EDNA [204-1]
EDTA [176-1]
EFFLUX PUMP [147-1]
EFFLUX PUMP GENES [41-1]
ENTEROBACTER CLOACAE [75-1]
ENTEROBACTERALES [83-1], [144-1], [152-1], [157-1], [169-1]
ENTEROBACTERALES, [153-1]
ENTEROBACTERIACEAE [163-1]
ENTEROCOCCAL COLONIZATION [228-1]
ENTEROCOCCAL INFECTION [195-1], [228-1]
ENTEROCOCCUS [79-1]
ENTEROCOCCUS FAECALIS [123-1], [127-1], [195-1], [228-1]
ENTEROCOCCUS FAECIUM [195-1], [228-1]
ENTEROINVASIVE ESCHERICHIA COLI [184-1]
EPIDEMIOLOGIC [126-1]
EPIDEMIOLOGICAL SURVEILLANCE [115-1]
EPIDEMIOLOGY [55-1], [73-1], [142-1], [223-1]
ESBL [217-1]
ESCHERICHIA COLI [65-1], [66-1], [102-1], [164-1]
EWE [51-1]
EXOENZIMES [37-1]
EXTENDED-DRUG RESISTANCE [152-1]
F4A [199-1]
FLUOROQUINOLONE [66-1]
GASTRIC CANCER [59-1]
GBS [160-1]
GENETIC MARKER [104-1]
GESTANTES [124-1]
GIARDIA SPP. [74-1]
GRAM-NEGATIVE [139-1]
GRAM-NEGATIVE BACILLI [104-1]
GRAM-NEGATIVE BACTERIA [178-1], [206-1]
GRAM-POSITIVE BACTERIA [206-1]
GREEN SYNTHESIS [108-1]
GROUP B STREPTOCOCCUS [132-1]
GUT BACTERIA [185-1]
HA-MRSA [84-1]
HEALTHCARE-ASSOCIATED INFECTIONS [222-1]
HEALTHCARE-ASSOCIATED INFECTIONS (HAIS) [130-1]
HEAVY METALS [79-1]
HELICOBACTER PYLORI [59-1]
HIV [126-1]
HOSPITAL ENVIRONMENT [229-1]
HOSPITAL INFECTION [70-1]
IDENTIFICATION [35-1]
IMMUNOSUPRESSED INFECTION [229-1]
IN VITRO ACTIVITY [104-1]
INCFIB [140-1]
INCIDENCE [73-1], [74-1]
INCQ1 [201-1]
INFECTION [131-1], [139-1]
INFECTIOUS DISEASES [119-1]
INFECTIOUS UVEITIS [106-1]
INFRARED ANALYSIS [151-1]
INNOVATION [219-1]
INTENSIVE CARE UNITS5. [222-1]
INTRAMAMMARY INFECTION [51-1]
INVASIVE CANDIDIASIS [223-1]
IRAS [114-1], [165-1]
KEFIR GRAINS [202-1]
KLEBSIELLA PNEUMONIAE [49-1], [64-1], [134-1], [140-1], [161-1], [224-1], [225-1]
KLEBSIELLA VARIICOLA [201-1]
KPC [161-1]
KPC-2 [64-1]
LABORATORIAL DETECTION [163-1]
LATIN AMERICA [226-1]
LIPIDS [80-1]
LOW-LEVEL LIGHT THERAPY [118-1], [119-1]
MβL [176-1]
MACROPHAGES [149-1]
MALDI-TOF [83-1], [111-1]
MALDI-TOF MS [129-1], [157-1]
MBT-ASTRA [103-1]
MDR [217-1]
MEROPENEM [141-1]
METABARCODING [185-1]
METALLIC NANOPARTICLES [108-1]
METHICILLIN-RESISTANT STAPHYLOCOCCUS SPP [105-1]
METHYLENE BLUE [102-1], [118-1]
MICROBIAL SENSITIVITY TESTS [119-1]
MICROBIOLOGICAL ANALYSIS [164-1]
MICROBIOLOGICAL PROFILE [115-1]
MICROBIOME [120-1]
MICROSPORIDIOSIS [146-1]
MIMUSOPS CORIACEA [108-1]
MINIMAL INHIBITORY CONCENTRATION [137-1]
MINIMUM INHIBITORY CONCENTRATION (MIC) [127-1]
MLST [41-1]
MOLECULAR BIOLOGY [68-1]
MOLECULAR DIAGNOSIS [184-1]
MOLECULAR EPIDEMIOLOGY [45-1], [151-1]
MOLECULAR TYPING [36-1], [64-1]
MONOPHASIC SALMONELLA [36-1]
MRSA [84-1], [133-1], [156-1], [193-1]
MULTIDRUG RESISTANCE [65-1], [153-1]
MULTIDRUG-RESISTANT [147-1]
MULTIDRUG-RESISTANT TUBERCULOSIS [55-1]
MULTIRRESISTANCE [199-1]
MURINE MODEL [210-1]
MYCOBACTERIUM INFECTIONS [68-1]
MYCOBACTERIUM SENEGALENSE. [68-1]
MYCOBACTERIUM TUBERCULOSIS [55-1]
NANOCARRIERS [139-1]
NASAL COLONIZATION [84-1]
NATURAL COMPONENTS [90-1]
NDM, IMP, VIM [176-1]
NEISSERIA GONORRHOEAE [22-1]
NEONATAL INTENSIVE CARE UNIT [143-1]
NEW DELHI METALLO-BETA-LACTAMASE [153-1]
NG CARBA-5 [96-1]
NOSOCOMIAL KLEBSIELLA PNEUMONIAE [220-1]
NOVEL β-LACTAMS/β-LACTAMASE INHIBITORS [152-1]
OMICS [231-1]
ONE HEALTH [217-1]
ONE-HEALTH [123-1], [144-1]
OPPORTUNISTIC PATHOGEN [146-1]
ORAL CAVITY [200-1]
OUTBREAK [141-1]
OUTBREAKS [151-1]
OXA-23 [162-1]
PANDEMIC [126-1]
PARA [73-1]
PARACOCCIDIOIDOMYCOSIS [210-1]
PATHOGEN [219-1]
PCR [106-1]
PCR MULTIPLEX [184-1]
PEDIATRIC [223-1]
PEDIATRIC PATIENTS [161-1]
PEDIATRICS [64-1]
PFGE [35-1], [36-1]
PHENOTYPIC AND GENOTYPIC CARBAPENEMASE M [169-1]
PHENOTYPIC TESTS [159-1]
PHOTOSENSITIZER [102-1]
PHYTOBACTER DIAZOTROPHICUS [151-1]
PLASMID [75-1]
PLASMIDS [140-1]
PNEUMONIA [146-1]
POLICIMBAC [225-1]
POLYMYXIN [111-1]
POLYMYXIN B [98-1], [225-1]
POLYMYXIN B RESISTANCE [40-1], [169-1]
POLYMYXIN B; [157-1]
POLYMYXIN RESISTANCE [163-1]
POLYMYXINS SUSCEPTIBILITY TEST [224-1]
PORPHYROMONAS GINGIVALIS [204-1]
POULTRY [11-1]
PREGNANT WOMAN [105-1]
PREVENÇAO [124-1]
PROBIOTIC PROPERTIES [202-1]
PROPHAGES [41-1]
PROPOLIS [127-1], [206-1]
PROTEINS [200-1]
PSEUDOMONAS AERUGINOSA [159-1], [199-1]
PUBLIC HEALTH [74-1]
QUALITATIVE [157-1]
RESISTANCE [70-1], [128-1]
RESISTANCE TO ANTIMICROBIALS [156-1]
RIFAMPICIN [40-1]
RMTASES [162-1]
RNASEQ [149-1]
RPOB [35-1]
SALMONELLA [11-1]
SALMONELLA INFANTIS [45-1]
SALMONELLA TYPHIMURIUM [41-1]
SALMONELLA TYPHIMURIUM ST313 [149-1]
SARS-COV-2 [105-1], [129-1], [185-1], [195-1], [231-1]
SARS-COV2 [126-1]
SCCMEC [193-1]
SECONDARY METABOLITE [198-1]
SECONDARY-INFECTION [67-1]
SEPSE NEONATAL [124-1]
SEPSIS [111-1]
SERRATIA MARCESCENS [141-1]
SEVERITY [210-1]
SHIGELLA SPP [184-1]
SODIUM SALICYLATE SALT [224-1]
SSCMEC TYPING [105-1]
ST103 [132-1]
STAPHYLOCOCCAL DISEASES [193-1]
STAPHYLOCOCCUS [121-1]
STAPHYLOCOCCUS AUREUS [65-1], [84-1], [118-1], [133-1], [154-1], [156-1]
STAPHYLOCOCCUS EPIDERMIDIS [154-1]
STREPTOCOCCUS AGALACTIAE [124-1], [131-1], [132-1], [160-1]
STREPTOCOCCUS SANGUINIS [200-1], [221-1]
STRYPHNODENDRON ADSTRIGENS [137-1]
SURGICAL WOUND INFECTION [115-1]
SURVIVAL ANALYSIS [55-1]
SUSCEPTIBILITY [142-1], [157-1]
SUSCEPTIBILITY PROFILE [121-1]
SWAB NASAL [156-1]
SYNERGISM [39-1]
SYNERGY [44-1], [178-1]
SYSTEMATIC REVIEW [226-1]
SYSTEMIC MYCOSES [210-1]
TOTAL COLIFORMS [164-1]
TRAIL [59-1]
TRANSFORMATION [221-1]
TRICHOPHYTON RUBRUM [39-1]
TUBERCULOSIS [73-1], [113-1]
UNDERREPORTING [126-1]
URINARY TRACT [66-1]
VANCOMYCIN [121-1]
VIROME [219-1]
VIRULENCE [37-1], [75-1], [186-1], [210-1]
VIRULENCE FACTORS [11-1], [79-1]
VIRULENCE GENES [45-1]
VRE [123-1]
WATER QUALITY [164-1]
WHOLE GENOME SEQUENCING [132-1]
WHOLE-GENOME SEQUENCING [45-1]
WOUNDS [118-1], [119-1]
WOUNDS INFECTIONS [118-1]